Sanofi launches clinical research to provide personalized disease management for diabetic patients
September 16, 2014 Source: People's Network
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Recently, France Sanofi launched the BEYOND series of clinical research projects in China, and will conduct an integrated analysis of the clinical data of the system to gain an in-depth understanding of the treatment needs and current status of Chinese diabetic patients, design a personalized disease management program for medical institutions. Advise the patient himself.
It is reported that the number of diabetic patients in China has reached 114 million, accounting for about one-third of the number of patients with diabetes worldwide. The number of patients has reached 100% within 10 years, and the number of patients with pre-diabetes has reached 148 million.
Weng Jianping, the chairman of the Diabetes Branch of the Chinese Medical Association and the vice president of the Third Affiliated Hospital of Sun Yat-sen University, said that in the next decade, diabetes treatment should fully consider the patient's disease characteristics and medication characteristics, and provide a more personalized treatment plan. Among them, basal insulin will play a more important role.
However, compared with the increasing use of basal insulin, there is still a lack of systematic large-scale clinical data for such drugs. The specific characteristics of Chinese patients with diabetes, the characteristics of basal insulin medication, etc. need further study.
The BEYOND series of studies, combined with the use of long-acting basal insulin for 10 years in Chinese diabetic patients, plans to use six clinical trials around the basic clinical research and application of basal insulin for five years. The dose, the target value of the patient's fasting blood glucose, post-discharge management, etc., find the best treatment plan according to the characteristics of Chinese patients with diabetes.
So how do patients prevent and control themselves? Pierre Chancel, senior vice president of Sanofi's Global Diabetes Division, believes that early diagnosis and treatment are key. He said: "In Europe and the United States, the time difference between patients being diagnosed with diabetes and using insulin for treatment is about 8-10 years. This time difference is too long, because the patient's insulin secretion capacity has been lost by 50% during the diagnosis. ."
According to Pierre Chancel, patients need to remember an important number - glycosylated hemoglobin is below 7.
In view of the current trend of mobile medical care for the management of chronic diseases, Lin Jinrong, vice president of Sanofi China Diabetes Division, stressed that to improve the diagnostic rate or blood sugar control, in addition to drug treatment, you can also pass the latest communication technology and equipment. Follow up on the health status of blood sugar to strengthen management. For example, through a blood glucose meter that can be connected to a mobile phone, the blood glucose number is seen on the mobile phone, the corresponding record is recorded, or the information is forwarded to the doctor to realize remote disease management.
Pierre Chancel said: "Diabetes is a complex disease. Dealing with diabetes is an expensive process that cannot be achieved by one side. So we need to work with the government, the medical community, the scientific community, and other companies to introduce more. The solution, and the introduction of more educational programs to help patients, to more successfully manage diabetes disease."
Gummy Candy,Gummy Worms,Sweet Candy,Soft Candy
Montreal Shantou Food Co., Ltd , https://www.montrealsnack.com